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Abstract
Background: Several parameters of the tumor microenvironment, such as hypoxia, inflammation and angiogenesis, play a
critical role in tumor aggressiveness and treatment response. A major question remains if these markers can be used to stratify
patients to certain treatment protocols.
The purpose of this study was to investigate the inter-relationship and the prognostic significance of several biological and
clinicopathological parameters in patients with head and neck squamous cell carcinoma (HNSCC) treated by radiotherapy ±
chemotherapy.
Methods: We used two subgroups of a retrospective series for which CT-determined tumoral perfusion correlated with local
control. In the first subgroup (n = 67), immunohistochemistry for carbonic anhydrase IX (CA IX) and glucose transporter-1
(GLUT-1) was performed on the pretreatment tumor biopsy. In the second subgroup (n = 34), enzyme linked immunosorbent
assay (ELISA) was used to determine pretreatment levels of the cytokines vascular endothelial growth factor (VEGF) and
interleukin-6 (IL-6) in serum. Correlation was investigated between tumoral perfusion and each of these biological markers, as
well as between the markers mutually. The prognostic value of these microenvironmental parameters was also evaluated.
Results: For CA IX and GLUT-1, the combined assessment of patients with both markers expressed above the median showed
an independent correlation with local control (p = 0.02) and disease-free survival (p = 0.04) with a trend for regional control (p
= 0.06).
In the second subgroup, IL-6 pretreatment serum level above the median was the only independent predictor of local control
(p = 0.009), disease-free survival (p = 0.02) and overall survival (p = 0.005).
Conclusion: To our knowledge, we are the first to report a link in HNSCC between IL-6 pretreatment serum levels and
radioresistance in vivo. This link is supported by the strong prognostic association of pretreatment IL-6 with local control, known
to be the most important parameter to judge radiotherapy responses.
Furthermore, the combined assessment of CA IX and GLUT-1 correlated independently with prognosis. This is a valuable 
indication that a combined approach is important in the investigation of prognostic markers.
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Background
Different biological and clinicopathological parameters
next to the commonly used tumor and nodal stage have
been proposed to help stratifying patients to certain treat-
ment protocols. Specifically, molecular properties of the
tumor microenvironment such as hypoxia, inflammation
and angiogenesis are currently investigated to serve as a
target for therapy[1].
The aim of the present research was to evaluate potential
prognostic markers in a retrospective series of HNSCC
treated by radiotherapy ± chemotherapy. A recently pub-
lished report on a retrospective series of patients with a
primary HNSCC treated by radiotherapy ± chemotherapy
and investigated by dynamic contrast-enhanced per-
fusion-computer tomography (perfusion-CT), indicated
that low tumoral perfusion predicted poor local control
(LC), when stratified according to the median perfusion
value [2]. This patient group was now used for further
exploration.
Our first hypothesis was that CT-determined tumoral per-
fusion could be a surrogate marker for hypoxia, which is
an important negative prognostic factor in radiation treat-
ment of HNSCC [3,4].
For this purpose, we evaluated the correlation of tumoral
perfusion with the expression of carbonic anhydrase IX
(CA IX) and glucose transporter-1 protein (GLUT-1) using
immunohistochemistry. These antigens are possible
intrinsic markers of hypoxia, both mainly controlled by
the hypoxia inducible factor-1 (HIF-1) pathway. Their
clinical relevance to assess the expression pattern and the
relation with hypoxia has been suggested by others for
several tumors [5-8].
CA IX is a transmembrane carbonic anhydrase involved in
the reversible hydration of carbon dioxide to carbonic
acid. It is a widely investigated protein, overexpressed in
many tumor types [9]. In HNSCC, its expression is associ-
ated with worse prognosis [6,10].
GLUT-1 mediates cellular glucose uptake and thus facili-
tates anaerobic glycolysis. This protein is largely undetec-
table in normal epithelium and benign tumors, but is
expressed in several types of human carcinomas such as
HNSCC and associated with poor prognosis [5,7,8,11].
Correlation was assessed between tumoral perfusion and
each of these intrinsic markers, as well as between CA IX
and GLUT-1 mutually. The prognostic value of these
immunohistochemical parameters was also evaluated.
Our second hypothesis was that the CT-determined
tumoral perfusion could be linked with the measurement
of vascular endothelial growth factor (VEGF) and inter-
leukin-6 (IL-6).
VEGF is a pro-angiogenic cytokine known to stimulate the
proliferation and migration of endothelial cells and to
promote vessel permeability. It is one of the hypoxia-
responsive genes, upregulated by increased levels of HIF-
1 [12,13]. VEGF serum levels are elevated in patients with
HNSCC compared to healthy controls [12,14,15]. A neg-
ative prognostic role for circulating VEGF serum levels has
been indicated for laryngeal carcinoma [15].
IL-6 is a proinflammatory cytokine produced by inflam-
matory cells as well as tumor cells [14,16]. In cancer
patients, it has a multifunctional role concerning systemic
alterations like cachexia as well a loco-regional impact on
for example tumor cell motility and intercellular adhe-
sion. Although mainly involved in inflammatory reac-
tions, its expression can be induced by the transcription
factor nuclear factor-kappaB (NF-κ B) under hypoxic con-
ditions [17]. Increased serum IL-6 levels have been
detected in several tumor types, having a prognostic
meaning for some of them [18-20]. The possible involve-
ment of IL-6 in radioresistance was mentioned in several
in vitro publications [21-23].
Available serum samples were analysed to evaluate VEGF
and IL-6 at pretreatment time using an enzyme linked
immunosorbent assay (ELISA).
We intended to evaluate the prognostic value of these
serum cytokines, as well as the possible link between
tumoral perfusion and the cytokine levels. This link could
be established by the hypoxia mediated HIF-1 or NF-κ B
pathways.
The present work results on the possible prognostic signif-
icance of different biological and clinicopathological
parameters studied in a retrospective study of patients
with HNSCC. Furthermore, the relationship with CT-
determined tumoral perfusion was investigated.
Methods
Patients and tissues
Between March 1995 and January 2000, patients with a
primary HNSCC treated by radiotherapy ± chemotherapy
were investigated by perfusion-CT to evaluate tumoral
perfusion. The largest axial tumor diameter was selected
and dynamic CT sequences were taken during injection of
a contrast agent bolus. Perfusion was correlated with the
carotid artery [2].
The original patient population was divided into two sub-
groups. For the first subgroup of 67 patients (group A), we
had the disposal of formalin-fixed, paraffin-embeddedBMC Cancer 2005, 5:42 http://www.biomedcentral.com/1471-2407/5/42
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biopsies, taken at the time of diagnostic endoscopy. Serial
sections, 5 µm thick, were stained for hematoxylin and
eosin (H&E) to allow evaluation of the representativity of
the biopsy specimen, and immunohistochemically for CA
IX and GLUT-1.
For the second subgroup of 34 patients (group B), we had
the disposal of serum samples taken at pretreatment time
and stored at -20°C until time of ELISA-analyses for VEGF
and IL-6. For 24 patients of this subgroup, we had the dis-
posal of other patient-related parameters, such as weight
loss, performance status, and sedimentation rate deter-
mined at the same pretreatment time.
Histological diagnosis was made by an independent
pathologist. Clinical data regarding local recurrence,
regional recurrence, disease-free and overall survival were
available for a minimum follow-up of four years. Patients'
Table 1: Patient characteristics, tumor characteristics and 
treatment modalities
Group A 
(n = 67)
Group B 
(n = 34)
Age (years) mean (min-max) 56 (36–82) 58 (42–79)
Sex M6 0 3 1
F7 3
cT stage T1 2 1
T2 17 13
T3 27 7
T4 21 13
cN stage N0 15 11
N1 12 3
N2 31 17
N3 9 3
Tumor site glottic 3 2
supraglottic 16 10
hypopharynx 20 7
oropharynx 24 14
oral cavity 2 0
nasopharynx 2 1
Radiotherapy 66 Gy/ 2 Gy 20 4
70 Gy/1.4 Gy 4 1
70 Gy/2 Gy 41
(2+ cisplatinum)
28 
(1+cisplatinum)
80.5 Gy/1.15 Gy 2 
(1+cisplatinum)
1
(+ cisplatinum)
Patient characteristics, tumor characteristics and treatment modalities 
are shown for Group A and Group B, both subgroups of the original 
study of CT-determined tumoral perfusion in patients with HNSCC 
treated by radiotherapy ± chemotherapy. Cisplatinum was given at a 
dose of 100 mg/m2 on days 1, 22 and 43.
cT: clinical tumor stage. cN: clinical nodal stage. M: male. F: female. Gy: 
Gray.
Example of immunohistochemistry for CA IX Figure 1
Example of immunohistochemistry for CA IX. Exam-
ple of biopsy stained for CA IX (×100). This tumor was 
scored highly positive.
Example of immunohistochemistry for CA IX Figure 2
Example of immunohistochemistry for CA IX. Exam-
ple of biopsy stained for CA IX (×100). This tumor showed a 
small positive percentage.BMC Cancer 2005, 5:42 http://www.biomedcentral.com/1471-2407/5/42
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characteristics and treatment schedules are shown in
Table 1.
Immunohistochemistry – Group A
CA IX
After dewaxing and rehydrating, an endogenous peroxi-
dase block (0.3% H2O2 in methanol) was applied for 30
minutes. Slides were rinsed with Phosphate Buffered
Saline (PBS) and Phosphate Buffer Saline with 0.4%
Tween 20 (PBST) and then incubated with a mouse mon-
oclonal anti-human CA IX antibody (M75, 1/50 dilution
in PBS; Bayer, USA) [24] for 30 minutes at room temper-
ature. After 3 × 5 min rinses in PBST, incubation with a
secondary anti-mouse labeled polymer/horse radish per-
oxidase conjugate solution (HRP, 30 minutes at room
temperature) was carried out before rinsing 3 more times.
Visualization was performed by diaminobenzidine (DAB)
substrate (DAKO, Substrate Chromogen System). After
rinsing in PBS, sections were counter-stained with Harris
hematoxylin (Merck). Slides were then dehydrated and
mounted with "micromount mounting medium" (Surgi-
path 03731). Substitution of the primary antibody with
PBS was used as a negative control. To exclude nonspecific
binding of the primary antibody, we performed the same
protocol using an irrelevant antibody of the same species
(monoclonal mouse anti-human Smooth Muscle Actin,
DAKO, 1/100 dilution). This showed no binding (data
not shown). As a positive control, we used normal gastric
mucosa. Representative examples of positive and negative
staining results are shown in Figure 1 and Figure 2,
respectively.
GLUT-1
After dewaxing and rehydrating, antigen retrieval was per-
formed by microwaving sections immerged in 10 mM cit-
rate buffer (pH 6). After cooling down, sections were
rinsed with Tris Buffered Saline, pH 7,5 with 0.1% Tween
20 (TBST) and an endogenous peroxidase block (3%
H2O2 in destilled water) was applied for 15 minutes.
Slides were rinsed with TBST and incubated with "Protein
Block Serum Free" (DAKO) for 20 minutes to block non-
specific binding of immunoglobulins to the tissue. In a
next step, sections were incubated with a polyclonal rab-
bit anti-human GLUT-1 antibody (DAKO, 1/200 dilution
in TBS) at 4°C overnight. After 3 × 5 minutes rinses with
TBST, incubation with a secondary anti-rabbit labeled
polymer/HRP conjugate solution (30 minutes at room
temperature) was carried out before rinsing 3 more times.
Visualization, counter-staining, dehydrating and mount-
ing was done as for the CA IX staining. Omitting of the
primary antibody served as a negative control. To exclude
nonspecific binding of the primary antibody, we per-
formed the same protocol using an irrelevant antibody of
the same species (polyclonal rabbit anti-human S-100,
DAKO, 1/300 dilution). This showed no binding (data
not shown). Erythrocytes, present in every section, served
as internal positive control for GLUT-1. Representative
examples of positive and negative staining results are
shown in Figure 3 and Figure 4, respectively.
Example of immunohistochemistry for GLUT-1 Figure 3
Example of immunohistochemistry for GLUT-1. 
Example of biopsy stained for GLUT-1 (×40). This tumor was 
scored highly positive.
Example of immunohistochemistry for GLUT-1 Figure 4
Example of immunohistochemistry for GLUT-1. 
Example of biopsy stained for GLUT-1 (×40). This tumor 
showed a small positive percentage.BMC Cancer 2005, 5:42 http://www.biomedcentral.com/1471-2407/5/42
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Quantification technique
All morphologic investigations were performed by the
same investigator, who was blinded to the clinical and fol-
low-up data.
The representativity of the biopsies was evaluated on the
H&E slices. All the tissue figuring in the biopsy was classi-
fied into one of the following compartments: viable
invasive tumor cells, carcinoma in situ, normal epithe-
lium, necrotic tissue, blood vessels, collagenous connec-
tive tissue, muscle tissue, inflammatory connective tissue,
and a "residu". The proportion of each of these compart-
ments was measured by means of a point counting sys-
tem. At an optical magnification of 100 × and using a grid
with 10 matched points, at least 100 points per tissue sec-
tion were counted as hitting one or another compartment.
The proportion of points fitting each compartment
yielded directly the volume proportions of the corre-
sponding compartments.
CA IX and GLUT-1 immunostained sections were semi-
quantitatively scored. The fraction of cells stained was
expressed as a percentage of the total tumor area, both
fractions being estimated by light microscopic inspection
of between 1 and 25 low power fields (×40) per patient.
Serum VEGF and IL-6 immunoassay – Group B
ELISA kits for specific cytokines (VEGF and IL-6) were
used according to the manufacturer's protocol (Quantik-
ine Human VEGF/IL-6 Immunoassay, R&D Systems, Min-
neapolis, MN). Serum samples were incubated in
duplicate on microtiter plates coated with a specific mon-
oclonal antibody for 2 hours at room temperature. The
plates were washed to remove unbound antibody. After
incubation of a conjugate solution, a substrate solution
was added. Color development was stopped after 20–25
minutes, depending on the assay. A microplate reader was
used to determine colorimetric densities at 570 nm and
450 nm for each sample. The readings at 570 nm were
subtracted from those at 450 nm to get the optical density
for each sample. Final results were calculated from a
standard curve generated by a form parametric logistic
curve fit. Results were expressed in pg/ml.
Statistics
The association between discrete and continuous varia-
bles was tested by the Mann Whitney's U-test or Kruskall
Wallis test as appropriate. Correlations between
continuous variables were obtained using Spearman's
rank correlation. Survival curves were constructed using
the Kaplan-Meier method, all time intervals being calcu-
lated from the date of the first radiotherapy session. Indi-
vidual factors were evaluated for their predictive value by
the log rank test. The Cox proportional hazard model was
used for multiple regression analysis. All tests were two-
sided, using a significance level of 0.05. All statistics were
done using Statistica software 6.
Results
Group A: immunohistochemistry
Representativity of the biopsies
On average, the biopsies were composed of viable tumor
cells (52.4%, range 9.76%–92.13%), carcinoma in situ
(1.3%), normal epithelium (2.0%), necrotic tissue
(2.8%), blood vessels (6.0%), collagenous connective tis-
sue (17.8%), muscle tissue (1.4%), inflammatory connec-
tive tissue (14.0%), and a "residu" (mucous glands i.e.;
2.8%). Because of their high tumor content the biopsies
were considered as representative to score tumoral expres-
sion of CA IX and GLUT-1.
Biological and clinicopathological parameters
The CT-determined perfusion rate ranged from 12.4 ml/
min/100 g to 274.4 ml/min/100 g with a median value of
87.9 ml/min/100 g (n = 67). The percentage of CA IX pos-
itivity ranged from 0 to 87.8% with a median of 17.14%,
and the GLUT-1 from 0 to 100% with a median of 67.5%.
Both stainings were almost exclusively membranous,
except for some aspecific cytoplasmatic CA IX staining.
There was no significant correlation between the CT-
determined tumoral perfusion and percentage positivity
for CA IX or GLUT-1.
We also found no significant correlation between tumor
characteristics such as tumor stage, nodal stage and differ-
entiation on one hand and perfusion-CT, CA IX and
GLUT-1 percentages on the other hand.
Correlation with outcome
In univariate analysis, the prognostic value of different
clinicopathological and biological parameters towards
local control (LC), regional control (RC), disease-free sur-
vival (DFS) and overall survival (OS) was evaluated.
The tumor stage (T3-4 vs. T1-2) predicted a poorer RC
(48.7 vs. 73.3% at 2 years; p = 0.03) and OS (43.7 vs.
64.6% at 5 years; p = 0.002). N3 stage also seemed to pre-
dict poorer outcome (LC: 9.8 vs. 44.8% at 2 years, p =
0.04; RC: 17.6 vs. 62.7% at 2 years, p = 0.0009; DFS: 0 vs.
37.9% at 5 years, p = 0.03; OS: 0 and 56.7% at 5 years, p
= 0.002). No significant correlation was found between
tumor differentiation and outcome.
Poorer tumor perfusion stratified according to the median
value was linked with poorer LC (33.2 vs. 48.2 % at 2
years, p = 0.03) and DFS (26.4 vs. 38.6% at 5 years, p =
0.03).BMC Cancer 2005, 5:42 http://www.biomedcentral.com/1471-2407/5/42
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For the CA IX and GLUT-1 percentages we could not find
a significant correlation with outcome. Nevertheless, a
trend towards poorer LC (31.4 vs. 44.6% at 2 years p =
0.08) and DFS (27.8 vs. 34.7% at 5 years, p = 0.08) was
seen in patients with CA IX as well as GLUT-1 values
above the median.
The multivariate analysis included tumor stage (T3-4 vs.
T1-2), nodal stage (N0-1-2 vs. N3), differentiation grade,
perfusion (≥  median) and combined CA IX and GLUT-1
percentages (CA IX and GLUT-1 ≥  median).
As shown in Table 2, the combined CA IX and GLUT-1
percentage was an independent prognostic factor for LC
(p = 0.02) and DFS (p = 0.04) with a trend for RC (p =
0.06). N3 stage was a strong independent predictor of LC
(p = 0.006), RC (p = 0.0001), DFS (p = 0.0001) and OS (p
= 0.0002). Higher tumor stage predicted poorer overall
survival (p = 0.006). The perfusion showed no clear corre-
lation with LC (p = 0.09).
Group B: serum immunoassay
Biological and clinicopathological parameters
The CT-determined tumoral perfusion rate ranged from
29.6 ml/min/100 g to 263.6 ml/min/100 g with a median
value of 88.7 ml/min/100 g (n = 34). IL-6 values ranged
from 0.4 pg/ml to 57.3 pg/ml with a median of 5.4 pg/ml.
VEGF values ranged from 73.5 pg/ml to 1613.1 pg/ml
with a median of 326.9 pg/ml.
There was no significant correlation between the per-
fusion-CT measurements, IL-6 and VEGF values. How-
ever, Figure 5 shows that the perfusion was borderline
inversely related to VEGF (p = 0.06) suggesting lower per-
fusion being associated with higher serum VEGF levels.
Patients with higher nodal stage showed significantly
more elevated IL-6 serum levels (p = 0.04). Other tumor
characteristics such as tumor stage and differentiation
grade were not correlated with either perfusion-CT, serum
VEGF or serum IL-6 levels.
Correlation with outcome
In univariate analysis, the prognostic value of IL-6, VEGF
and clinicopathological parameters towards LC, RC, DFS
and OS was evaluated.
As clear from Figures 6 and 7, the IL-6 serum level, strati-
fied according to the median, was found to have a predic-
tive value towards LC (9.3 vs. 70.4% at 2 years, p = 0.03),
DFS (8.6 vs. 57.7% at 5 years, p = 0.05) and OS (11.9 vs.
74.9% at 5 years, p = 0.0009). Tumor stage, nodal stage
and tumoral perfusion were found to have only a border-
line prognostic value, probably due to the small sample
size in this group (data not shown). We found no
correlation between pretreatment cytokine serum levels
and other patient-related parameters such as weight loss,
performance status and sedimentation rate determined at
the same pretreatment time.
The multivariate analysis included tumor stage (T3-4 vs.
T1-2), nodal stage, perfusion (≥  median), VEGF serum
level (≥  median) and IL-6 serum level (≥  median). Table 3
shows that the IL-6 serum level was the only independent
predictor of LC (p = 0.009), DFS (p = 0.02) and OS (p =
0.005).
Discussion
The tumor microenvironment plays a critical role in
tumor aggressiveness and treatment response. Several
microregional features have been shown to be relevant for
treatment outcome, such as hypoxia, inflammation and
angiogenesis. The major question stays whether these
markers can be used in an integrated way to stratify
patients to certain treatment options [1].
Starting from a retrospective series of patients with
HNSCC treated by radiotherapy ± chemotherapy, we
investigated the prognostic significance of several biolog-
ical and clinicopathological parameters. Earlier estab-
lished results showed that for this whole patient group,
CT-determined tumoral perfusion was correlated with
poorer LC [2].
Table 2: Multivariate analysis for Group A
Local Control Regional Control Disease-free Survival Overall Survival
Parameter RR 95% CI P value RR 95% CI P value RR 95% CI P value RR 95% CI P value
T1-2 vs. T3-4 1.21 0.58–2.53 0.62 2.74 0.99–7.62 0.05 1.40 0.70–2.83 0.34 3.85 1.46–10.18 0.006
N 0-1-2 vs. N3 3.75 1.47–9.60 0.006 7.68 2.72–21.70 0.0001 5.70 2.34–13.85 0.0001 6.05 2.32–15.77 0.0002
Differentiation 1.50 0.90–2.49 0.12 1.64 0.89–3.02 0.11 1.49 0.93–2.40 0.12 0.81 0.45–1.47 0.49
Perfusion > median 0.55 0.28–1.09 0.09 1.07 0.46–2.51 0.87 0.61 0.32–1.15 0.12 0.65 0.48–0.88 0.28
GLUT-1 & CA IX > median 2.33 1.12–4.82 0.02 2.24 0.97–11.58 0.06 2.06 1.05–4.07 0.04 1.53 0.65–3.60 0.33
Multivariate analysis (Cox proportional hazard model) for Group A towards local control, regional control, disease-free survival and overall survival. 
Significant P values are marked in bold. RR: relative risk. CI: confidence interval.BMC Cancer 2005, 5:42 http://www.biomedcentral.com/1471-2407/5/42
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Two subgroups were now used for further analysis. In the
first subgroup of 67 patients, immunohistochemistry for
CA IX and GLUT-1 was performed on a representative par-
affin-embedded pretreatment biopsy. In the second
subgroup of 34 patients, ELISA was used to determine pre-
treatment VEGF and IL-6 serum levels. The correlation
between these parameters mutually, as well as their prog-
nostic value, was investigated.
Hypothesizing that CT-determined tumoral perfusion
could be an inverse marker for hypoxia (less perfusion
relates to more hypoxia), we assessed the correlation
between tumoral perfusion, the intrinsic hypoxia markers
CA IX and GLUT-1, and the serum levels of VEGF and IL-
6, known to be upregulated under certain microenviron-
mental conditions like hypoxia.
Besides a borderline inverse association between per-
fusion and VEGF, no significant correlation was found in
our study. There are three possible explanations in sup-
port of this finding.
First, it is likely that the dynamic CT measures rather acute
hypoxia, while CA IX and GLUT-1, as well as VEGF and IL-
6, are more indicative for chronic hypoxia.
Second, the CT-determined tumoral perfusion in this
patient group was a measurement that took place through
Correlation between CT-determined tumoral perfusion and pretreatment VEGF serum levels Figure 5
Correlation between CT-determined tumoral perfusion and pretreatment VEGF serum levels. There was a 
trend for poorer CT-determined tumoral perfusion to correlate with higher pretreatment VEGF serum levels (rS = -0.32, p = 
0.06; n = 34).BMC Cancer 2005, 5:42 http://www.biomedcentral.com/1471-2407/5/42
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one region of interest, i.e. the maximum diameter of the
tumoral region. On the other hand, CA IX and GLUT-1
immunohistochemistry was performed on one tumor
biopsy taken at the periphery of the tumor field, and VEGF
and IL-6 values were measured as systemic serum levels.
Third, the relationship between perfusion and oxygena-
tion has shown to be in a precious balance [1,25].
The borderline association found between perfusion and
VEGF can be explained through the hypoxia-hypothesis.
Nevertheless, an opposite finding would also have been
possible, associating the angiogenetic property directly
with perfusion.
The further analysis of the biological and clinicopatholog-
ical parameters showed that patients with higher nodal
stage expressed significantly higher IL-6 serum levels. This
experience is in accordance with previous reports linking
elevated IL-6 levels to extensive disease [20], and more
specifically, to lymph node involvement [26]. It is not sur-
prising since this multifunctional cytokine plays an
important role in promoting tumorigenesis.
Concerning the prognostic value of the clinicopathologi-
cal parameters, we found a correlation with outcome for
known factors like tumor stage (RC and OS) and N3 stage
(LC, RC, DFS, OS). Of these, only the nodal stage
appeared to behave as an independent prognostic factor
for RC and DFS.
Kaplan-Meier curve local control analysis Figure 6
Kaplan-Meier curve local control analysis. There was a significant difference in local control between patients with pre-
treatment IL-6 serum levels above and below the median (9.3 vs. 70.4% at 2 years, p = 0.03).BMC Cancer 2005, 5:42 http://www.biomedcentral.com/1471-2407/5/42
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Concerning the prognostic value of the biological param-
eters, poorer tumor perfusion predicted poorer LC and
DFS, as expected [2]. This correlation was lost in the
smallest subgroup, probably due to a too small patient
number in this group. Furthermore, in multivariate anal-
ysis, the perfusion only kept a borderline prognostic value
for outcome.
For CA IX and GLUT-1, the combined assessment of
patients with both markers expressed above the median
did indicate an independent correlation with worse LC,
RC and DFS. This result demonstrates that a combined
assessment gives additive information, though we have to
note that the prognostic value of each of both markers is
not clearly established, given prognostic [5-8,27] as well
as non-prognostic [28] publications.
In the second subgroup, IL-6 pretreatment serum level
stratified according to the median seemed to be the only
independent predictor of LC, DFS and OS. VEGF pretreat-
ment levels were not correlated with prognosis.
The prognostic value of IL-6 has been described in many
tumor types [18], but not yet in HNSCC treated by radio-
therapy ± chemotherapy. In our multivariate analysis, we
found a strong prognostic impact of the IL-6 pretreatment
serum level on local control. This might indicate that
there is indeed a link between IL-6 and radioresistance, as
already shown in vitro by others [21-23].
Kaplan-Meier curve overall survival analysis Figure 7
Kaplan-Meier curve overall survival analysis. There was a highly significant difference in overall survival between patients 
with pretreatment IL-6 serum levels above and below the median (11.9 vs. 74.9% at 5 years, p = 0.0009)BMC Cancer 2005, 5:42 http://www.biomedcentral.com/1471-2407/5/42
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VEGF- reports in literature are a bit conflicting, with
papers demonstrating [15] and denying [29] a prognostic
role for VEGF serum levels at pretreatment time.
In this study, due to methodological reasons, we per-
formed serum and immunohistochemical analyses for
two subgroups instead of the whole patient group.
The advantage of using serum samples over immunohis-
tochemistry on biopsies is that the ELISA test is quickly
and simple to perform. Furthermore, the technique is not
too invasive and quite established.
On the other hand we must be aware that HNSCC cells
may not be the only source of the elevated serum cytokine
levels in patients. The serum levels may also depend in
part upon individual host inflammatory responses and
conditions like cachexia, and certainly not upon hypoxia
only. In our patient group however, we did not see a cor-
relation between VEGF or IL-6 serum levels and sedimen-
tation rates, determined at the same pretreatment time.
Furthermore, there are some pitfalls in the measurement
of these cytokines [30]. Concerning VEGF, the isoform
specificity and platelet interaction may be of influence.
The use of banked frozen serum for analysis may also be
perceived as a shortcoming. Because of the retrospective
character of this study, we could not control the methods
used for taking and storing the serum samples.
Conclusion
In conclusion, we found a prognostic value in this series
of patients with HNSCC treated by radiotherapy ± chem-
otherapy for some of the investigated parameters, with a
major role for IL-6. To our knowledge, we are the first to
report a link in HNSCC between IL-6 pretreatment serum
levels and radioresistance in vivo. This link is supported by
the strong prognostic association of pretreatment IL-6
with local control, known to be the most important
parameter to judge radiotherapy responses. This finding
has to be validated in other, preferably prospective,
studies.
Furthermore, the combined assessment of CA IX and
GLUT-1 correlated independently with prognosis. This is
a valuable indication that a combined approach is impor-
tant in the investigation of prognostic markers.
We believe that additional to the standard TNM classifica-
tion this combined assessment of several biological and
clinicopathological parameters will show most appropri-
ate to stratify patients to certain treatment protocols. The
efforts made to search for prognostic factors in radiother-
apy settings will stretch towards a more efficient combina-
tion of radiotherapy with other treatment strategies like
chemotherapy, radiosensitizers, bioreductive drugs and
biological targeting. Therefore, further research will be
necessary.
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